Loading…
Employees: 2,169
Size Viva Biotech (1873.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $354M, the 846th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$1.33 on 6 Nov 2026.
Performance Over six months the shares fell 14.4%, against -32.3% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 6th highest of 18 in its peer set.
Growth Revenue grew 7.4% over the last twelve months (peer median -8.8%); the operating margin is 9.9% (peer median -385.3%).
Valuation It trades at 9.5× forward earnings.
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.7 points below its cost of capital (11.7% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.13B | HK$1.88B | HK$2.15B | HK$2.38B | HK$2.77B |
| Revenue growth | — | -13% | -10% | -14% | — |
| Gross profit | HK$736M | HK$711M | HK$745M | HK$816M | HK$949M |
| EBITDA | HK$440M | HK$438M | HK$481M | HK$446M | HK$525M |
| Net income | HK$199M | HK$238M | HK$181M | -HK$128M | -HK$615M |
| Free cash flow | HK$323M | HK$98.0M | HK$162M | HK$187M | HK$80.4M |
| Capital expenditure | HK$168M | HK$133M | HK$208M | HK$193M | HK$271M |
| Total debt | n/a | HK$1.48B | HK$1.37B | HK$2.10B | HK$3.17B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1873.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.0% | -17.2% | 10th lowest of 20 |
| 6-month return | -14.4% | -32.3% | 6th highest of 18 |
| Distance from 52-week high | -53.3% | -53.8% | 10th highest of 20 |
| Revenue growth (TTM) | +7.4% | -8.8% | 6th highest of 16 |
| Operating margin | 9.9% | -385.3% | 2nd highest of 16 |
| Forward P/E | 9.5× | n/a | — |
| Growth the price implies (Req g, 7 yrs) | 5.6% | n/a | — |
| Growth delivered (Del g) | +19.1% | n/a | — |
| Hurdle (Req g minus delivered) | -13.5 pp | n/a | — |
| ROIC minus cost of capital | -7.7 pp | -80.5 pp | 2nd highest of 11 |
| EV / EBITDA | 5.9× | n/a | — |
| Net debt / EBITDA | -0.4× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 9.5× | 5.6% | +19.1% |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 11.4× | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | n/a | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | n/a | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | n/a | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 18.7× | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | n/a | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | n/a | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | n/a | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $328M | -57% | n/a | -57% | n/a | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $325M | n/a | +395% | -173% | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | n/a | n/a | n/a |